Evidence map›Paper›PMID 42003004›Full record

ArticleMovement disorders clinical practice2026

Continuous Apomorphine Infusion in Multiple System Atrophy Real-World Insights From a French Nationwide Retrospective Cohort.

Simon Lamy, Frederique Leh, Alexandra Foubert-Samier, Soizic Leguy Bonnet, Guillaume Baille, Margherita Fabbri, Margaux Dunoyer, Lise Mantisi, Caroline Giordana, Anaïs El Ouartassi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Simon LamyDepartment of Neurology, Pontchaillou University Hospital, Rennes, France.ORCID https://orcid.org/0000-0001-9303-3642
Frederique LehDepartment of Neurology, Pontchaillou University Hospital, CIC INSERM 1414 Rennes, Rennes, France.
Alexandra Foubert-SamierCHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, CRMR AMS, Bordeaux, France.
Soizic Leguy BonnetCabinet de Neurologie Libérale, Saint-Malo, France.
Guillaume BailleDepartment of Neurology, Rothschild Foundation Hospital, Paris, France.ORCID https://orcid.org/0000-0002-0248-5772
Margherita FabbriDepartment of Clinical Pharmacology and Neurosciences, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS-Park/F-CRIN Network, University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France.
Margaux DunoyerDepartment of Neurology, CRMR MSA, Pitié-Salpêtrière Hospital, APHP, Paris, France.
Lise MantisiDepartment of Neurology-Parkinson's Disease Expert Center, Institute of Neurology, AP-HP, Pitié-Salpêtrière University Hospital, Paris, France.
Caroline GiordanaDepartment of Neurology, NS-PARK/FCRIN Network, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
Anaïs El OuartassiNeurology Department, Centre Hospitalier d'Antibes, Antibes, France.
Olivier RascolFrench National Reference Center for MSA, Clinical Investigation Centre CIC1436, Department of Neurosciences and Clinical Pharmacology, and NS-Park/FCRIN Network, University of Toulouse, University Hospital of Toulouse, INSERM, Toulouse, France.
Wassilios G MeissnerDepartment of Neurology for Neurodegenerative Diseases, University Hospital Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0003-2172-7527
David BendetowiczCHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, CRMR AMS, Bordeaux, France.
Marie VanelCabinet de neurologie, Cesson Sévigné, France.
David GrabliSorbonne Université, Paris Brain Institute, Inserm, CNRS, Paris, France.
Fabienne Ory-MagneDepartment of Neurology, Toulouse Parkinson Expert Centre, INSERM, UMR1214 Toulouse NeuroImaging Centre TONIC, University Hospital of Toulouse, Toulouse, France.
Sophie DrapierDepartment of Neurology, Pontchaillou University Hospital, CIC INSERM 1414 Rennes, Rennes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContinuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA).

objectiveTo assess the 6-month efficacy and tolerability of CSAI in MSA patients.

methodsFrench multicenter retrospective registry-based analysis of CSAI use in MSA. The primary outcome was the 6-month clinical response using the Clinical Global Impression Improvement (CGI-I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.

resultsFifty patients were included; 94% had MSA-P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% "much," 54% "minimally"), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good/excellent in 74%; 20% reported somnolence and/or orthostatic hypotension.

conclusionIn selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short-term clinical benefit with acceptable tolerability.

Indexed as

apomorphinefluctuationsinfusionMSAparkinsonism

Identifiers

PMID42003004
PMCPMC13339362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.